'Achievements and goals are endless in health care,' says head of Turkey's AİFD

Secretary general and chief operating officer of Turkey’s Association of Research-Based Pharmaceutical Companies (AİFD) Osman Kara has underlined the importance of innovation in pharmaceuticals and recorded that there are new risks ahead of us in the field of health care towards 2050s. He spoke at the “Symposium on Biotechnological Products and Biosimilars” organized by the AiFD on the Development of Pharmaceutical Awareness and Rational Drug Use

Mr Kara stated that there will be need for new therapies and medicines due, among other things, the rapidly aging population, increase in chronic diseases and the emergence of new diseases, and indicated that technological medicinal products changed radically the treatment of life-threatening diseases. In his speech, Mr Kara also reminded that the aging population availed of the capacity to generate effective solutions for increasing healthcare needs and recorded that biotechnological methods enabled the development of new therapies for many serious diseases from a clinical and epidemiological perspective.

During the three-day symposium held with the interest and wide participation of the academic world as well as the private sector, public agencies and institutions and national and international organizations such as the World Health Organization, in addition to the Ministry of Health and the Social Security Institution (SGK), also sectorial business world organizations and associations such as the Association of Research-Based Pharmaceutical Companies (AİFD), were represented.